Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibudilast for amyotrophic lateral sclerosis
2019-003549-14Phase 2Terminated
- Sponsor
- MediciNova, Inc.
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ibudilast in amyotrophic lateral sclerosis (ALS) (3 arms), sponsored by MediciNova, Inc. Primary endpoints: Change from baseline in ALSFRS-R score at Month 12 and Survival time. Started Jan 2020; status: terminated.
02
Drugs
ibudilast
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on 2019-003549-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003549-14.